J&J, over 3.6 billion resources generated in 2020 in Italy

Over 3.6 billion euros in 2020 alone, the annus horribilis of the Covid-19 pandemic, equal to 0.2% of GDP. These are the resources generated by the American group Johnson & Johnson in Italy, where it is active with the 3 divisions Janssen Italia (pharmaceuticals), J&J Medical (medical devices) and J&J Consumer Health (health and beauty). Present on the national territory with 7 sites, for a total of 2,780 direct employees that exceed 11,400 counting indirect ones, the company has invested more than 212 million euros in the Peninsula in the last 5 years, which have produced an increase in the economic impact for over 400 million in the three-year period 2017-2020. So much is the ‘J&J galaxy’ in Italy, according to the photograph taken by a studio of The Hackett Group, presented in Milan. Among the flagships of the group is the Latina site in the heart of Lazio’s ‘pharma valley’, recognized as “one of the most important pharmaceutical hubs in the world”. Founded in 1980, the center has seen a leap in production that from 1.8 billion treatments in 2010 will reach 5 billion innovative oral treatments this year. Almost all of the ‘made in Latina’ therapies, 150 different preparations for over 50 different drugs, are destined abroad where they reach patients in more than 100 countries around the world. “Innovation, research and sustainability” are the levers used by J&J to create value. The company’s efforts are catalysed in particular by the green turning point, the objective of 3 Virtual Power Purchase Agreements (Vppa) recently signed in Europe to speed up the race towards an ambitious goal: to satisfy 100% of electricity needs from renewable sources. by 2025 in all the group’s sites, including the ‘tricolor’ ones. A mix of wind and solar power, the company proposes, will be able to generate around 270,000 megawatts / hour of electricity every year. AI, artificial intelligence, has also enabled the Latina plant to cut carbon dioxide emissions by 5,100 tons a year. While the annual reduction in CO2 emissions of the Pomezia pole will amount to -4,900 tons, thanks to a modern trigeneration system (electricity, heat and cooling). Green revolution, pink power. The massive presence of women in the workforce is traditionally one of the pride of J&J, which highlights the data relating to the roles of responsibility occupied by women as “particularly flattering”: in Janssen, for example, in executive positions they represent 39% and among middle managers ” 46%, compared to the national average measured by Manageritalia, equal to 18.3% and 30% respectively. Another element remarked by Johnson & Johnson is that, “in the absence of the group, Italy would have to face an unemployment rate higher than 5 basis points”. According to the study by The Hackett Group, in fact, for each directly employed by J&J, over 3 jobs are supported in the rest of the economy. Overall, there are more than 1,035 local suppliers with whom the various J&J companies have relationships. Finally, innovation: a land that the company does not stop cultivating in the ‘Italian garden’, reaping its fruits. “Janssen, in particular – underlines the company – has tripled the number of clinical studies conducted in the country, from 32 in 2017 to 98 in 2020, for a total of 346 centers involved, generating new knowledge for the health system both public and private, and in fact allowing patients free access to new treatments “. Numbers that stand out in the light of a recent study by Altems, the High School of Economics and Management of Health Systems of the Catholic University, according to which “for every euro invested in Research & Development by companies, 2.8 savings for the national system “. From oncology to hepatitis, from HIV to psoriasis, from pulmonary arterial hypertension to multiple sclerosis, the group’s research focuses on therapeutic areas still full of unmet needs. The analysis of The Hackett Group “returns a clear picture of the roots of the Johnson & Johnson group in Italy and of how, thanks to continuous investments, we have managed in recent years to generate more and more value in and for our country – he comments Massimo Scaccabarozzi, president of Janssen Italia and Head of External Affairs of J&J Italia – A value that is expressed on several fronts: from therapeutic solutions to the efficiency of production processes to reach more and more people with our preparations, to greater attention to environment through initiatives aimed at saving energy, reducing emissions and managing waste “. “Another cornerstone of the group’s value creation is innovation, which in Janssen’s case – the manager specifies – sees us constantly engaged in medical scientific research, directly involving Italian patients in almost 100 clinical trials in order to identify answers. to the unresolved health challenges “. Results “the result of the work of over 11 thousand people who directly or indirectly work with us, allowing us to contribute to the growth of the country”. It is to them that Scaccabarozzi’s thanks go.